Genmab A/S (NASDAQ:GMAB – Get Free Report) issued its quarterly earnings results on Thursday. The company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.36 by $0.20, Zacks reports. The firm had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.20 billion. Genmab A/S had a return on equity of 13.96% and a net margin of 16.97%.
Here are the key takeaways from Genmab A/S’s conference call:
- Genmab reported 22% revenue growth for the first nine months of 2026 and 9% growth in adjusted operating profit. Management said growth is becoming more diversified, with roughly half of revenue growth coming from outside DARZALEX.
- Commercial momentum continued: EPKINLY sales rose 47% to $491 million, while TIVDAK sales increased 9% to $131 million. Genmab highlighted broader EPKINLY adoption and continued TIVDAK growth in Japan and Europe.
- The company announced three positive Phase III readouts in October: EPKINLY in frontline DLBCL, Rina-S in platinum-resistant ovarian cancer, and petosemtamab in first-line head and neck cancer. Genmab sees potential launches beginning in 2027, though the medicines remain subject to regulatory review.
- Genmab maintained its 2026 guidance, expects revenue in the upper part of its $4.325–$4.525 billion range, and said adjusted operating profit should finish above the midpoint of its guidance range.
- Management cautioned that fourth-quarter operating expenses will rise significantly due to manufacturing, clinical development, and launch-readiness work for Rina-S and petosemtamab.
Genmab A/S Trading Up 1.7%
NASDAQ:GMAB traded up $0.89 during trading hours on Friday, hitting $53.63. The company had a trading volume of 7,827,783 shares, compared to its average volume of 6,032,240. Genmab A/S has a 1 year low of $23.62 and a 1 year high of $59.97. The company has a market cap of $33.47 billion, a P/E ratio of 45.84, a P/E/G ratio of 2.11 and a beta of 0.73. The company has a 50-day moving average of $39.18 and a 200 day moving average of $31.11. The company has a current ratio of 2.46, a quick ratio of 2.44 and a debt-to-equity ratio of 0.81.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently issued reports on the stock. Guggenheim upped their target price on shares of Genmab A/S from $58.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, October 30th. JPMorgan Chase & Co. raised shares of Genmab A/S from a “neutral” rating to an “overweight” rating in a research note on Monday, October 26th. Weiss Ratings upgraded shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, September 1st. Morgan Stanley boosted their price target on shares of Genmab A/S from $42.00 to $57.00 and gave the stock an “equal weight” rating in a research report on Friday, October 30th. Finally, TD Cowen upped their price objective on shares of Genmab A/S from $43.00 to $52.00 and gave the company a “buy” rating in a research note on Monday, October 26th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, Genmab A/S has an average rating of “Moderate Buy” and a consensus target price of $53.61.
Check Out Our Latest Report on Genmab A/S
Genmab A/S Company Profile
Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases.
The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.
Genmab operates internationally, with activities across Europe, North America and Asia.
Read More
- Five stocks we like better than Genmab A/S
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
